#United States #Burlington #Labcorp #melanoma #PGDx elio

Labcorp's New Companion Diagnostic for Advanced Melanoma

Labcorp, a renowned figure in laboratory services, has proudly announced the approval of its latest diagnostic tool, the PGDx elio® tissue complete CDx, by the U.S. Food and Drug Administration (FDA). This development represents a crucial step forward in the fight against advanced melanoma, particularly for patients with specific BRAF mutations who could benefit from targeted therapies.

Understanding Advanced Melanoma

Melanoma, deemed the most aggressive type of skin cancer, presents significant challenges with a stark five-year survival rate of merely 16% for those diagnosed with stage IV disease. Current medical advancements emphasize the importance of targeted therapies for a subset of advanced melanoma patients whose tumors possess BRAF mutations. The newly certified PGDx elio tissue complete CDx serves as a companion diagnostic that empowers clinicians by identifying patients carrying BRAF V600E/K variants, thereby guiding them to FDA-approved BRAF inhibitors and combinations of BRAF/MEK inhibitors.

Enhancing Patient Care Through Targeted Treatment

Dr. Shakti Ramkissoon, vice president and medical lead for oncology at Labcorp, emphasizes the life-saving potential of targeted therapies for advanced melanoma patients. He states, “Advanced melanoma is an extremely aggressive and life‑threatening cancer, but targeted treatments are offering real hope for patients.” By facilitating quicker access to treatment through reliable diagnostics, clinicians can confirm eligibility and initiate therapies without delay.

A Comprehensive Testing Solution

The PGDx elio tissue complete CDx is not just an innovation; it is a scalable solution intended for usage by trained healthcare professionals across hospitals and clinical laboratories, ensuring broader access to high-quality molecular testing. Its kit-based format allows for deployment directly within healthcare facilities, thus broadening access to necessary testing while retaining vital samples and data for ongoing research.

The introduction of this diagnostic tool is part of Labcorp's commitment to precision medicine, integrating molecular diagnostics to offer personalized care for oncology patients. The test not only detects a range of genetic alterations but also supports Labcorp's extensive portfolio in cancer care, reinforcing its leadership role in advancing health through innovation.

For any additional insights about the PGDx elio tissue complete CDx or Labcorp’s oncology services, interested parties can visit their detailed page here.

About Labcorp

Labcorp (NYSE: LH), recognized for its state-of-the-art laboratory services, plays a pivotal role in improving health outcomes through innovation. With approximately 71,000 skilled professionals serving clients in nearly 100 countries, Labcorp has become an integral partner in both diagnostics and drug development, significantly contributing to the majority of new drugs approved by the FDA in the year 2025. Their unwavering dedication to quality and service is evident in the over 750 million tests performed annually, empowering healthcare providers and patients alike in their quest for health.

In conclusion, the FDA's approval of Labcorp's PGDx elio tissue complete CDx marks a vital advancement in ensuring that patients with advanced melanoma receive timely and accurate treatments tailored to their specific genetic profiles. As the diagnostic landscape continues to evolve, Labcorp stands at the forefront, committed to enhancing patient care and outcomes worldwide.